Understanding the Genotoxicity of Tamoxifen?
By David H. Phillips, DSc, MRCPath
Oncology Spectrums Volume 2 No. 8
-
Development of STI571 and Its Use in Chronic Myelogenous Leukemia and Other Malignancies
By Michael J. Mauro, MD, Michael E. O’Dwyer, MD, and Brian J. Druker, MD
-
Pharmacy Practice
The Role of Chemoprotectants in Cancer Supportive Care
By Masha S. H. Lam, PharmD, and Robert J. Ignoffo, PharmD, FASHP
-
STI571: A Sea Change in Cancer Therapeutics or a One Time Event?
By Brian J. Druker, MD
-
Development of Antagonists of the Platelet-Derived Growth Factor Receptor Family
By Neill A. Giese, PhD, Nathalie A. Lokker, PhD, Jin-Chen Yu, PhD, Kenji Matsuno, PhD, Michio Ichimura, PhD, Shoji Oda, PhD, Robert Scarborough, PhD, and Anjali Pandey, PhD
-
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
-
Oncology Ethics Forum
Ethical Perspectives on Oncology Care
By Terri Maxwell, RN, MSN, AOCN
-
Letter From the Editors
Are You Ready For Some Ethics, Some Success, Some Cytoprotectants, and Some New Board Members?
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD